TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03964441

Intervention type: OTHER
Intervention: Parent interviews (optional organizational study)
Description: Interview with a sociologist or psychologist to explore perceptions of ES and the impact of the results, expectations regarding certain types of results not currently available, the emotional situation, and position regarding the continuation of the pregnancy At 4 different times: at inclusion, at the time of the CGA-array results, at the time of the ES results and at a distance from the ES results
Study: NCT03867344

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypoglycemic Hyperinsulinemic Clamp
Description: Participants undergo a 120-minute hypoglycemic hyperinsulinemic clamp procedure.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normoglycemic Hyperinsulinemic Clamp
Description: Participants undergo a 120-minute normoglycemic hyperinsulinemic clamp procedure.
Study: NCT04767763

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of TSH, fT3, fT4,TRH, TT3, TT4, rT3 in patients with CVVHDF
Description: blood samples were collected before initiation of CRRT and at 1,2,3,6,9-day following. Last samples were collected 3 days after the end of CRRT.
Study: NCT02308189

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise with blood flow restriction
Description: Low load resistance exercise performed with an external pressure cuff applied over both legs or both arms during respective leg and arm exercises.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Low load resistance exercise performed with no external pressure cuff applied to the appendicular limbs.
Study: NCT03822182

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liposomal bupivicaine
Description: The medication administered in the interscalene block is the intervention in this study. There are three different types of interscalene blocks that will be administered in order to compare the independent effectiveness of LB with the effectiveness of LB plus dexamethasone. Study participants will be randomized into one of three groups. The treatment groups are listed below:~Group 1 (Control): 30 ml of 0.5% bupivacaine and 0.4ml (4 mg) of dexamethasone Group 2: 15ml 0.5% bupivacaine and 10ml (133mg) of LB (Exparel) and 5.4ml normal saline Group 3: 5ml 0.5% bupivacaine and 10ml LB (Exparel) and 0.4ml (4 mg) dexamethasone and 5ml normal saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liposomal bupivicaine
Description: The medication administered in the interscalene block is the intervention in this study. There are three different types of interscalene blocks that will be administered in order to compare the independent effectiveness of LB with the effectiveness of LB plus dexamethasone. Study participants will be randomized into one of three groups. The treatment groups are listed below:~Group 1 (Control): 30 ml of 0.5% bupivacaine and 0.4ml (4 mg) of dexamethasone Group 2: 15ml 0.5% bupivacaine and 10ml (133mg) of LB (Exparel) and 5.4ml normal saline Group 3: 5ml 0.5% bupivacaine and 10ml LB (Exparel) and 0.4ml (4 mg) dexamethasone and 5ml normal saline

Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone
Description: steroid that will be used in control as well as in group 3 to see if effect with liposomal bupivicaine is prolonged as has been shown with standard bupivicaine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: steroid that will be used in control as well as in group 3 to see if effect with liposomal bupivicaine is prolonged as has been shown with standard bupivicaine.
Study: NCT00579878

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leflunomide
Description: A loading dose of 100 mg (or placebo) for three (3) days will be given. Following that three-day period, a dose of 20 mg/day will be maintained throughout the remainder of the study. This dose may be decreased to 10 mg/day at the discretion of the treating physician if minor toxicities occur (e.g., diarrhea, liver enzyme elevations
Study: NCT03396835

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVSENSOR00009
Description: All subjects who are enrolled into the test group and participate in data collection receive both the INVSENSOR00009 and the control sensor simultaneously on the forehead.
Study: NCT02565056

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self help book + telephone support
Description: Self-help book based upon principles of Acceptance and Commitment Therapy
Study: NCT02887261

Intervention type: DEVICE
Group type: OTHER
Intervention: BardPowerPort sip Implantable Port
Description: capable for power injection for contrast media.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Port
Description: not for power injection for contrast media.
Study: NCT00583843

Intervention type: PROCEDURE
Intervention: Ultrasound
Description: Ultrasound weekly during initial fields of radiation, and daily during the boost phase.
Study: NCT02593565

Intervention type: OTHER
Intervention: Online questionnaires
Description: Women will be asked to complete questionnaires during their pregnancy and a postpartum questionnaire.
Study: NCT00882882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers Squibb

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers Squibb
Study: NCT01672840

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 5g Cocoa Consumption
Description: Daily consumption of 10g Extra Dark cholocate and a beverage containing 2.5g of cocoa powder for 8 weeks
Study: NCT03964441

Intervention type: OTHER
Intervention: Parent interviews (optional organizational study)
Description: Interview with a sociologist or psychologist to explore perceptions of ES and the impact of the results, expectations regarding certain types of results not currently available, the emotional situation, and position regarding the continuation of the pregnancy At 4 different times: at inclusion, at the time of the CGA-array results, at the time of the ES results and at a distance from the ES results

Intervention type: OTHER
Intervention: parent questionnaire (optional organizational study)
Description: To evaluate the experience, perceptions, the impact of the analyses on the decision, satisfaction and concerns regarding the ES and its results, opinions on certain types of results not currently available, as well as anxiety and possible psychological distress At 4 different points in time: at inclusion, at the delivery of the CGA-array results, at the delivery of the ES results and at a distance from the delivery of the ES results

Intervention type: OTHER
Intervention: parent questionnaire (optional organizational study)
Description: To evaluate the experience, perceptions, the impact of the analyses on the decision, satisfaction and concerns regarding the ES and its results, opinions on certain types of results not currently available, as well as anxiety and possible psychological distress At 4 different points in time: at inclusion, at the delivery of the CGA-array results, at the delivery of the ES results and at a distance from the delivery of the ES results

Intervention type: OTHER
Intervention: professional interviews (optional organizational study)
Description: interview to understand how the decision is formed

Intervention type: OTHER
Intervention: Focus group for professionals (optional organizational study)
Description: interview to specify whether variants of unknown significance) VUS will potentially be returned to the clinicians, or even to the patient via the clinician.
Study: NCT03321474

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: modified gull wing preparation
Description: preparation is the inciso - proximal extension of porcelain laminates veneer margin more palatally.~The preparation finished at the gingival margin and extended towards the papilla to finish the interproximal elbow preparation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: modified gull wing preparation
Description: preparation is the inciso - proximal extension of porcelain laminates veneer margin more palatally.~The preparation finished at the gingival margin and extended towards the papilla to finish the interproximal elbow preparation.
Study: NCT01621906

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 18F-FLT-PET Imaging
Description: All patients will be imaged using FLT-PET scans at baseline (within 4 weeks of initiation of WBRT), 7-10 days after completion of WBRT and then 10-12 weeks after WBRT.~Patients will also be evaluated with MRI imaging at baseline and then 10-12 weeks after WBRT.~Patients will be followed with MRI every 3 months (+/- 7 days) for the first year and then every 6 months (+/- 7 days) thereafter which is the standard of care.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 18F-FLT-PET Imaging
Description: All patients will be imaged using FLT-PET scans at baseline (within 4 weeks of initiation of WBRT), 7-10 days after completion of WBRT and then 10-12 weeks after WBRT.~Patients will also be evaluated with MRI imaging at baseline and then 10-12 weeks after WBRT.~Patients will be followed with MRI every 3 months (+/- 7 days) for the first year and then every 6 months (+/- 7 days) thereafter which is the standard of care.
Study: NCT05085769

Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: A procedure for morbidly obese patients whose body mass index (BMI) is higher than 40 kg/m2 or 35 kg/m2 and having comorbidities of obesity.
Study: NCT03298893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Injection
Description: 2 possible doses : flat dose 240 mg q2 weeks or 1mg/kg q2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 40 mg/m2, once a week during radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Intensity-modulated radiation therapy (including volumetric-modulated arc therapy and tomography) will be used. A dose of 45 Gy will be delivered to the pelvis in 25 fractions of 1.8 Gy using a 6-MV photon energy.~An additional dose of 54 Gy in 25 fractions of 2.16 Gy may be delivered to invaded lymph nodes using SIB-IMRT.~An additional lateral pelvic dose may be delivered if coverage of the target volumes is judged insufficient. The volumes, doses and techniques will be those usually used in each center.
Study: NCT01672840

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 10g Cocoa Consumption
Description: Daily consumption of 20g Extra Dark cholocate and two beverage containing 2.5g of cocoa powder each for 8 weeks
Study: NCT01276990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 224436
Description: Oral drinking solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 224436
Description: Oral drinking solution
Study: NCT02806687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gene Therapy product CYL-02
Description: Gene Therapy product CYL 02 = = plasmid DNA encoding SST2 + DCK::UMK genes pre-complexed to linear polyethylenimine.~Intratumoral injection of the gene therapy product CYL-02 (2,5 ml within the primary tumor under endoscopic ultrasound guidance an under propofol anaesthesia). The intratumoral injection of CYL-02 is followed by three IV infusions of Gemcitabine (1000 mg/m2) at 48 hours and then every week. A second Intratumoral injection of the gene therapy product CYL-02 is performed at a same dosage and volume, 30 days after the first administration followed by three infusions of gemcitabine (1000 mg/m2) according the same rhythm (48 hours and every week) and dose. Patients have infusion of Gemcitabine 3 weeks/month during 6 months (or until progression).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine alone 3 weeks/month during 6 months (or until progression).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine alone 3 weeks/month during 6 months (or until progression).
Study: NCT04546152

Intervention type: DEVICE
Intervention: HYAPROF® SOFT and HYAPROF® BALANCE
Description: Dermal filler injection to different facial areas

Intervention type: DEVICE
Intervention: HYAPROF® SOFT and HYAPROF® BALANCE
Description: Dermal filler injection to different facial areas
Study: NCT03600181

Intervention type: DEVICE
Intervention: RAD - 97 pulse co-oximeter
Description: non-invasive sensor capable of measuring ORI (Rainbow® Sensor, R2-25, Revision L, Masimo Corp.) will be applied to the third or fourth finger on the contralateral side of the inflatable cuff for non-invasive blood pressure monitoring.~Values from the RAD 97 monitor will be blinded to clinicians who perform intubation (clinical research nurse will be in charge of watching RAD 97 monitor)
Study: NCT02376660

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oats
Study: NCT02608840

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auditory stimulation during sleep
Description: The intervention is a brain computer interface program which measures brain electroencephalogram to identify slow waves and time the sounds. Barely audible sounds are delivered through headphones and played during sleep (specifically, during slow wave sleep).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auditory stimulation during sleep
Description: The intervention is a brain computer interface program which measures brain electroencephalogram to identify slow waves and time the sounds. Barely audible sounds are delivered through headphones and played during sleep (specifically, during slow wave sleep).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Intervention
Description: The brain electroencephalogram is measured and headphones are worn, but sounds are not played during sleep.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Intervention
Description: The brain electroencephalogram is measured and headphones are worn, but sounds are not played during sleep.
Study: NCT00603564

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Castar Starmed (CPAP) delivered by a helmet
Description: Continuous Positive Airway Pressure delivered by a helmet with PEEP valve of 10 cmH2O and FiO2 0.5
Study: NCT02060045

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bundle implementation
Study: NCT00500318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium Bromide
Description: Aclidinium Bromide, 200μg. Once daily oral inhalation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose matched placebo, once daily oral inhalation.
Study: NCT03609242

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STOP-HPV bundle intervention
Description: This intervention will be the bundle (training in communication skills, with the addition of performance feedback followed by the addition of provider prompts).
Study: NCT03844828

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IOL implantation experimental
Description: Mono- or bilateral implantation of trifocal toric intraocular lenses POD FT. If both eyes of the same patient qualify for the implantation of a trifocal toric lens, a bilateral implantation will be performed. If only one eye qualifies for a trifocal toric lens, the contralateral eye will be implanted with the spherical trifocal IOL POD F (both lenses: (PhysIOL, Liège, Belgium).
Study: NCT00625326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COL-121
Description: 75 µg/g COL-121 Ointment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 50 µg/g Calcipotriene Ointment
Description: 50 µg/g Calcipotriene Ointment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COL-121
Description: 150 µg/g COL-121 Ointment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COL-121
Description: 300 µg/g COL-121 Ointment
Study: NCT01196117

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: 14 days of placebo therapy
Description: 14 days of placebo therapy - use of guaifenesin with salivary cortisol measurement and Epworth Sleepiness Score (ESS) documentation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 14 days of CPAP therapy
Description: 14 days of continuous positive airway pressure (CPAP) therapy with salivary cortisol measurement and Epworth Sleepiness Score (ESS) documentation
Study: NCT01911104

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 10 weeks of aerobic exercise
Study: NCT04474093

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Zirconium-reinforced glass ceramics(ZRGC),Lithium disilicate glass ceramics(LGC), Resin infiltrated glass ceramics(RIGC)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Zirconium-reinforced glass ceramics(ZRGC),Lithium disilicate glass ceramics(LGC), Resin infiltrated glass ceramics(RIGC)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Zirconium-reinforced glass ceramics(ZRGC),Lithium disilicate glass ceramics(LGC), Resin infiltrated glass ceramics(RIGC)
Study: NCT00579878

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate-Sulfasalazine-Hydroxychloroquine
Description: Methotrexate:~dosing starts at 10mg/week (4 tabs/wk). If total remission (according to ACR criteria found in Appendix II) has not been achieved and the labs are acceptable at the 8-week evaluation, the dose increased to 15 mg/week (6 tabs/wk);at the 16-week evaluation, the dose increased to 20 mg/week (8 tabs/wk). This dose will remain stable until the end of the study.~Sulfasalazine: dosing will start at 500 mg bid (1000 mg/day). This dose will remain steady until the 24-week evaluation. If total remission has not been achieved by this time and the labs remain acceptable,dose will be increased to 1000 mg bid (2000 mg/day) Hydroxychloroquine: dosing will be started and maintained throughout the study at 200 mg bid (400 mg/day).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leflunomide-Sulfasalazine-Hydroxychloroquine
Description: Leflunomide: dose of 100 mg (or placebo) for three (3) days. Followed by a dose of 20 mg/day will be maintained throughout the remainder of the study. dose may be decreased to 10 mg/day at the discretion of the treating physician if minor toxicities occur Sulfasalazine: dosing will start at 500 mg bid (1000 mg/day). This dose will remain steady until the 24-week evaluation. If total remission has not been achieved by this time and the labs remain acceptable, dose will be increased to 1000 mg bid (2000 mg/day) Hydroxychloroquine: dosing will be started and maintained throughout the study at 200 mg bid (400 mg/day).
Study: NCT02128932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Injected subcutaneously (under the skin) once weekly. Following 4 doses (4 weeks) of 0.25 mg semaglutide weekly subjects will receive 0.5 mg semaglutide weekly for 26 weeks.
Study: NCT04115033

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alpha-stim
Description: The device for both groups is the Alpha-stim, a FDA-approved device similar to the Military Field Stimulator (MFS/Neuro-Stim System), a cranial electrical stimulation (CES) device.
Study: NCT02128932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Injected subcutaneously (under the skin) once weekly. Following 4 doses (4 weeks) of 0.25 mg semaglutide weekly subjects will receive 0.5 mg semaglutide weekly for 26 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Injected subcutaneously (under the skin) once daily. Subjects will start on 10 IU once daily and the dose will be adjusted according to fasting plasma glucose.
Study: NCT03414229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: 100mg bid days 1-21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: 100mg bid days 1-21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: 100mg bid days 1-21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: 100mg bid days 1-21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg/dose Day 1, Q 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg/dose Day 1, Q 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg/dose Day 1, Q 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg/dose Day 1, Q 3 weeks
Study: NCT01663025

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hand Reflexology
Description: The hand reflexology will begin in theatre, before the local anaesthetic is administered and will continue until the patient is ready to leave the operating theatre.
Study: NCT02837146

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ)
Description: Induction phase: TCZ subcutaneously (162 mg weekly) from baseline to week 24

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Description: Induction and maintenance phase: Methotrexate 15-20 mg/week from baseline to week 54
Study: NCT04500171

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Colocare Instruction Sheet: SAM + CAM SMOG
Description: Suitability and Comprehensibility Assessment of Materials (SAM + CAM). The SAM + CAM is comprised of 22 evaluation items within the 6 original categories. The SMOG is a readability assessment tool that uses a formula to calculate grade levels by the number of sentences, total number of words in the sentences, and the number of polysyllabic words
Study: NCT01276990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 224436
Description: Oral drinking solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 224436
Description: Oral drinking solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 224436
Description: Oral drinking solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 224436
Description: Oral drinking solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 224436
Description: Oral drinking solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BI 224436
Description: Oral drinking solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 224436
Description: Oral drinking solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral drinking solution
Study: NCT02955069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: PDR001 was administered at a dose of 400 mg via intravenous infusion once every 4 weeks (Q4W). PDR001 was administered on Day 1 of every cycle. Each cycle was 28 days.